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iﬁcation of the cohort using the predictive parameters “cumu-
lated complication events avoided” (CCEA) and “life years
gained” was more effective to identify those patients with a high
real-life improvement of outcomes than using others. Clinical
parameters performed particularly poorly even if they were com-
bined. For example, for the sub-cohort selected using highest
potential for “CCEA” the life expectancy increased by 0.26 years
per patient, but decreased by 0.29 if stratiﬁed by the risk factor
HbA1c > 7.5%. CONCLUSIONS: Individualised Predictive
Disease Modeling is a valuable strategy to identify patients with
the highest potential to avoid diabetes related complications.
This powerful strategy should be used to improve the effective-
ness and efﬁciency of DMPs for D.m.
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OBJECTIVES: To compare health care service utilization and
medication adherence in an elderly (age ≥ 65 years) population
newly starting thiazolidinedione therapy with patients starting
insulin or other oral antidiabetic medications in the same period.
METHODS: This was a retrospective data analysis using a
Medicare HMO database. We compared adherence, health care
service utilitzation, and cost impact of starting thiazolidinediones
for 12 months after initiation of therapy. A total of 165 patients
starting thiazolidinedione therapy between July 1999 and
December 2001 were compared with patients starting insulin (n
= 82) and other oral antidiabetic medication (n = 288). Propen-
sity scores were created by using variables from a comprehen-
sive health status assessment and health care claims data in the
year prior to beginning new antidiabetic medication and utilized
in multivariate analyses examining predictors of health care costs
and diabetes medication adherence in the year following start of
therapy. RESULTS: Patients starting thiazolidinedione therapy
had 56% higher medication adherence than did patients starting
insulin (P < 0.01) and had adherence comparable with that in
patients starting other oral antidiabetic medications (after con-
founder adjustment). There were no health care cost differences
between patients starting either drug therapy. CONCLUSIONS:
The introduction of thiazolidinedione therapy in an elderly type
2 diabetic population was associated with improved adherence
compared with insulin and with no increases in health care costs.
The usefulness of propensity scores in the bias reduction and bal-
anced sample selection while determining outcomes associated
with introduction of new pharmacotherapies is highlighted
through these ﬁndings.
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OBJECTIVE: Patient preferences are crucial in treatment deci-
sion-making when several equally efﬁcacious alternative treat-
ments are available. The objective of this study was to investi-
gate the principal drivers of treatment preference among indi-
viduals with type-2 diabetes. METHODS: We conducted 11
focus groups with 84 adults with type-2 diabetes supplemented
with treatment preference driver checklists. RESULTS: The ﬁrst
5 focus groups yielded 10 drivers of treatment preference. The
second 6 focus groups ranked the importance of the 10 drivers
among 100 points. The principal driver of treatment preference
was medication effectiveness with an average score of 36.2 out
of 100. The next two highly-rated drivers were treatment ﬂexi-
bility and physician recommendation (9.5 and 9.4, respectively),
followed by quality of life impacts and correct dosing (7.5 each),
ﬁnancial costs (7.3), treatment convenience (6.4), physical side
effects (6.3), emotional side effects (6.0), and treatment tolera-
bility (3.8). A full 62% of participants chose 5 or more drivers,
while only 12% chose one or two drivers. We then asked par-
ticipants to assume medication effectiveness was perfect and to
reallocate the 100 points among the remaining 9 drivers. In this
round, the principal driver of treatment preference was physical
side effects (17.4). The next most highly-rated drivers were ﬁnan-
cial costs and physician recommendation (12.9 and 12.2, respec-
tively), followed by correct dosing (11.1), treatment ﬂexibility
(10.9), quality of life impacts (10.1), treatment convenience
(9.4), emotional side effects (8.5), and treatment tolerability
(7.3). Only 8% of participants chose one or two drivers, 
while 38% chose 8 or more drivers. CONCLUSIONS: Great
variability exists in the drivers of treatment preference among
individuals with type-2 diabetes. Group averages mask tremen-
dous inter-individual variability in the importance of drivers 
and their relative rank. These ﬁndings underscore the need for
continued methodological work on the concept of treatment
preference.
MENTAL HEALTH
MH1
AN ECONOMIC ANALYSIS OF ANTIPSYCHOTIC TREATMENT
FOR SCHIZOPHRENIA
Lui G1, Sun SX1, Christensen DB1, Zhao Z2
1University of North Carolina at Chapel Hill, Chapel Hill, NC, USA;
2Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVE: Evaluate direct health care costs associated with
olanzapine and risperidone treatment for patients with schizo-
phrenia. METHODS: Using the North Carolina Medicaid
Claims database, patients diagnosed with schizophrenia (ICD9-
CM: 295) were assigned to olanzapine or risperidone cohort 
on the basis of which drug was received ﬁrst. Medication,
medical service and total health care costs were examined 
for schizophrenia-related, mental health related, and all-cause
services using multivariate models controlling for possible 
confounding factors including demographics, types of schizo-
phrenia, co-morbidities, and prior use of medications and
medical services. RESULTS: A total of 498 patients (286 olan-
zapine and 212 risperidone) were identiﬁed with available data
for three-month prior and eighteen-month after antipsychotic
treatment. During 18-month treatment, olanzapine patients
incurred signiﬁcantly higher drug expenditures (+$1235, p <
0.0001) than risperidone patients. Patients on olanzapine,
however, had signiﬁcantly lower medical service costs (-$3212,
p = 0.02) than risperidone patients, leading to no statistical 
difference in total health care costs between the two groups 
(-$1976 lower for olanzapine, p = 0.16). The ﬁndings are con-
sistent with the schizophrenia-related and mental health-related
cost models. Additionally, age, race, type of schizophrenia, 
